SightGlass reveals clinical study results

SightGlass Vision revealed results of studies into the safety and efficacy of its diffusion optics technology ophthalmic lenses in slowing the progression of myopia in children.  

The company’s Cypress study re-enrolled 98 participants from the original three-year clinical trial to gain an additional six months of data. 

SightGlass Vision said significant improvements in axial length and cycloplegic spherical equivalent refraction between the test and control groups were identified.  

Its lens used thousands of micro-dots to scatter light and reduce contrast on the retina, which the company said was a unique mechanism of action to control myopia progression in children.